Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2011 May-Jun;3(3):243-52.
doi: 10.4161/mabs.3.3.15234. Epub 2011 May 1.

Engineering the variable region of therapeutic IgG antibodies

Tomoyuki Igawa  1 , Hiroyuki Tsunoda, Taichi Kuramochi, Zenjiro Sampei, Shinya Ishii, Kunihiro Hattori
Affiliations
Review

Engineering the variable region of therapeutic IgG antibodies

Tomoyuki Igawa et al. MAbs. 2011 May-Jun.

Abstract

Since the first generation of humanized IgG1 antibodies reached the market in the late 1990s, IgG antibody molecules have been extensively engineered. The success of antibody therapeutics has introduced severe competition in developing novel therapeutic monoclonal antibodies, especially for promising or clinically validated targets. Such competition has led researchers to generate so-called second or third generation antibodies with clinical differentiation utilizing various engineering and optimization technologies. Parent IgG antibodies can be engineered to have improved antigen binding properties, effector functions, pharmacokinetics, pharmaceutical properties and safety issues. Although the primary role of the antibody variable region is to bind to the antigen, it is also the main source of antibody diversity and its sequence affects various properties important for developing antibody therapeutics. Here we review recent research activity in variable region engineering to generate superior antibody therapeutics.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Chan AC, Carter PJ. Therapeutic antibodies for autoimmunity and inflammation. Nature Rev Immunol. 2010;10:301–316. - PubMed
    1. Weiner LM, Surana R, Wang S. Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nature Rev Immunol. 2010;10:317–327. - PMC - PubMed
    1. Strohl WR. Therapeutic monoclonal antibodies-past, present and future. In: An Z, editor. Therapeutic Monoclonal Antibodies: From Bench to Clinic. New York: John Wiley & Sons; 2009. pp. 4–50.
    1. Strohl WR. Optimization of Fc-mediated effector functions of monoclonal antibodies. Curr Opin Biotechnol. 2009;20:685–691. - PubMed
    1. Batista FD, Neuberger MS. Affinity dependence of the B cell response to antigen: a threshold, a ceiling and the importance of off-rate. Immunity. 1998;8:751–759. - PubMed

MeSH terms

LinkOut - more resources

-